Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CLLS by emailGet an email when CLLS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CLLS, unsubscribe in one click. Privacy
📣 What CLLS Says Is Next
H1 2028 · “The Company plans to initiate a Phase 1 IIT in China and share the preliminary clinical data from this program in H1 2028.”
Company press release, Sep 14, 2026 · SEC filing
H2 2027 · “The Company plans to initiate a Phase 1 investigator-initiated trial (IIT) in China and share the preliminary clinical data from this program in H2 2027. .HEAL-201 Severe hypercholesterolemia remains a major driver of atherosclerotic cardiovascular disease, with many high-risk patients continuing to experience elevated low-density lipoprotein cholesterol (LDL-C) levels despite currently available therapies.”
Company press release, Sep 14, 2026 · SEC filing
Q4 2026 · “Cellectis expects to present the full Phase 1 dataset in Q4 2026.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
Dilution pressure:30 · Moderate
Cash runway not available
Shelf registration (F-3, Jul 2025) +10
Share count +57% in a year +20
Recent financing filings on SEC EDGAR:
Jul 2, 2025 · Shelf registration, up to $200M · F-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLLS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.